Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
A Multi-center Phase II Study Evaluating the Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST), Resistent or Intolerant to at Least Imatinib and Sunitinib
Sponsor: Bayer
A PHASE2 clinical study on Gastrointestinal Stromal Tumor, this trial is completed. The trial is conducted by Bayer and has accumulated 9 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Nov 2019 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
▶ Show 4 earlier versions
-
Apr 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Brigham and Women's Hospital
- Fox Chase Cancer Center
- Massachusetts General Hospital
- Oregon Health and Science University
- Suzanne George, MD
For direct contact, visit the study record on ClinicalTrials.gov .